TITLE

Off with the label and on the Avastin bandwagon: Why now and how far?

AUTHOR(S)
Gopal, K. S. Santhan
PUB. DATE
September 2009
SOURCE
Indian Journal of Ophthalmology;Sep2009, Vol. 57 Issue 4, p253
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article presents the author's views about the "off label" use of avastin by ophthalmologists. The author says that the ophthalmologist must be aware of the legal, financial, industrial and ethical implications of its use. The author further says that avastin certainly looks the best option from the point of view of all concerned including patient, physician and the funding agencies.
ACCESSION #
43247859

 

Related Articles

  • A Phase 3 Trial of Bevacizumab in Ovarian Cancer. Perren, Timothy J.; Swart, Ann Marie; Pfisterer, Jacobus; Ledermann, Jonathan A.; Pujade-Lauraine, Eric; Kristensen, Gunnar; Carey, Mark S.; Beale, Philip; Cervantes, Andr�s; Kurzeder, Christian; Bois, Andreas du; Sehouli, Jalid; Kimmig, Rainer; St�hle, Anne; Collinson, Fiona; Essapen, Sharadah; Gourley, Charlie; Lortholary, Alain; Selle, Fr�d�ric; Mirza, Mansoor R. // New England Journal of Medicine;12/29/2011, Vol. 365 Issue 26, p2484 

    Background: Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease. Methods: We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5...

  • Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma. Patel, Priti; Srinivas, Sandy // Current Clinical Pharmacology;Aug2011, Vol. 6 Issue 3, p181 

    The targeted therapies available to treat metastatic kidney cancer include vascular endothelial growth factor (VEGF) inhibitors, bevacizumab, sorafenib, sunitinib, pazopanib, and the mTor inhibitors temsirolimus and everolimus. These agents have significantly improved patient outcomes but are...

  • Peritumoral Apparent Diffusion Coefficient as a Metric of Response in Patients with Recurrent Glioblastoma Multiforme Treated with Bevacizumab and Irinotecan. Andre, J. B.; Lu, S.; Spearman, K.; Raval, S. N. // Neuroradiology Journal;Jun2008, Vol. 21 Issue 3, p350 

    Bevacizumab and irinotecan have shown promising results in patients with recurrent glioblastoma multiforme (GBM), which traditionally carries a poor prognosis after first-line therapies have been exhausted. Retrospectively documenting the short-term effects of this chemotherapeutic regimen on...

  • Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy. Masayasu Kitahashi; Takayuki Baba; Madoka Sakurai; Hirotaka Yokouchi; Mariko Kubota-Taniai; Yoshinori Mitamura; Shuichi Yamamot // Clinical Ophthalmology;2014, Vol. 8, p485 

    Background: The purpose of this study was to compare the effectiveness of pneumatic displacement combined with intravitreal bevacizumab (IVB) with that of pneumatic displacement (PD) alone to treat massive submacular hemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV). Methods:...

  • Caution urged for intravitreal injections of anti-VEGF agents in high-risk patients. Loughery, Jessica // Ocular Surgery News;9/25/2008, Vol. 26 Issue 18, p37 

    The article discusses several studies by researchers in Florida which showed that intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents can lead to immediate transient increases in intraocular pressure (IOP). Ronald E. P. Frenkel suggested ophthalmologists to be...

  • Basic steps reduce endophthalmitis risk from anti-VEGF injections. Hasson, Matt // Ocular Surgery News;9/25/2008, Vol. 26 Issue 18, p38 

    The article discusses a research on endophthalmitis associated with intravitreal anti-vascular endothelial growth factor (VEGF) therapy injections. It references a study by Richard F. Spaide and colleagues, published in the "American Journal of Ophthalmology." The study showed that the incidence...

  • Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Finger, R. P.; Charbel Issa, P.; Ladewig, M.; Holz, F. G.; Scholl, H. P. N. // British Journal of Ophthalmology;Apr2008, Vol. 92 Issue 4, p483 

    Purpose: To investigate the efficacy of intravitreal bevacizumab injections for treating choroidal neovascularisation (CNV) secondary to pseudoxanthoma elasticum (PXE). Methods: Patients with active CNV due to PXE received intravitreal bevacizumab (1.5 mg) and were reviewed at monthly intervals....

  • Optimal Protocols for the Anti-VEGF Tumor Treatment. Anita, S.; Hritonenko, N.; Marinoschi, G.; Swierniak, A.; Poleszczuk, J.; Piotrowska, M. J.; Foryś, U. // Mathematical Modelling of Natural Phenomena;Jul2014, Vol. 9 Issue 4, p204 

    Cancer treatment using the antiangiogenic agents targets the evolution of the tumor vasculature. The aim is to significantly reduce supplies of oxygen and nutrients, and thus starve the tumor and induce its regression. In the paper we consider well established family of tumor angiogenesis models...

  • Bevacizumab.  // Reactions Weekly;4/11/2009, Issue 1247/1248, p8 

    The article describes the case of a 51-year-old man with metastatic colorectal cancer who developed papules on his neck 2 months after taking bevacizumab. The lesions were mildly pruritic and showed adherent central keratotic plugs. Her skin biopsy revealed transepidermal collagen elimination...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics